MGXMetagenomi Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Metagenomi Therapeutics, Inc. against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MGXThis | $31M#6 | — | 0.3x#1 | 1.2x#3 | -51.8%#7 | -12.6%#6 | -380.9%#3 | -78.1%#4 | — | — | — | — |
| TVGN | $41M#1 | — | — | — | — | -91.4%#11 | — | — | — | — | — | — |
| INMB | $41M#2 | — | 2.0x#4 | 810.4x#8 | 257.1%#1 | -9.5%#5 | -94766.0%#9 | -225.9%#5 | -607.3%#1 | — | — | — |
| EXOZ | $38M#3 | — | 10.4x#6 | 541.8x#7 | — | -56.3%#10 | -13867.0%#8 | -250.6%#7 | — | — | — | — |
| PTHS | $37M#4 | — | — | 2.2x#4 | — | -444.6%#14 | -193.1%#2 | — | — | — | — | — |
| IRLA | $34M#5 | 0.3x#1 | — | — | — | -47.8%#9 | — | — | — | — | — | — |
| ALGS | — | — | — | — | -39.5%#5 | 81.6%#2 | -4024.9%#6 | -75.9%#3 | — | — | — | — |
| CVM | $24M#7 | — | 2.2x#5 | 92.6x#6 | 65.5%#2 | 5.6%#3 | -9396.5%#7 | -231.9%#6 | — | — | — | — |
| ESLA | $22M#8 | — | — | — | — | — | — | — | — | — | — | — |
| BSEM | $21M#9 | — | 0.8x#3 | 0.4x#1 | -31.8%#4 | -121.2%#12 | -1.5%#1 | -23.8%#2 | — | — | — | — |
| BKHA | $20M#10 | — | — | — | — | -30.6%#8 | — | — | — | — | — | 260.2%#1 |
| JSPR | $18M#11 | — | 12.6x#7 | — | — | 100.0%#1 | — | -0.0%#1 | — | — | — | — |
| ABOS | $17M#12 | — | 0.5x#2 | — | — | -18.6%#7 | — | -350.6%#8 | -1586.2%#2 | — | -89.0%#1 | — |
| SCLX | $16M#13 | — | — | 0.5x#2 | -46.5%#6 | -413.8%#13 | -1143.7%#4 | — | — | 4#1 | — | — |
| PLUR | $15M#14 | — | — | 14.9x#5 | -24.0%#3 | -5.5%#4 | -2454.5%#5 | — | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-11-02.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice